Gene Therapy in the Management of Erectile Dysfunction (ED): Past, Present, and Future
In the past, many researchers considered viral vectors to be the most promising candidates to transfer genetic material into the corpora for the treatment of erectile dysfunction. However, at present, no viral vectors have progressed to human trials. In contrast, the use of naked gene therapy, a pla...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2009-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/tsw.2009.102 |
| id |
doaj-4b4afededbe34dfcb6b93da9fc4f95ec |
|---|---|
| record_format |
Article |
| spelling |
doaj-4b4afededbe34dfcb6b93da9fc4f95ec2020-11-24T21:48:03ZengHindawi LimitedThe Scientific World Journal1537-744X2009-01-01984685410.1100/tsw.2009.102Gene Therapy in the Management of Erectile Dysfunction (ED): Past, Present, and FutureArnold Melman0Kelvin P. Davies1Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USADepartment of Urology, Albert Einstein College of Medicine, Bronx, NY, USAIn the past, many researchers considered viral vectors to be the most promising candidates to transfer genetic material into the corpora for the treatment of erectile dysfunction. However, at present, no viral vectors have progressed to human trials. In contrast, the use of naked gene therapy, a plasmid expressing the human Maxi-K potassium channel, is the only gene therapy treatment to be evaluated in clinical phase I trials to date. The success of these studies, proving the safety of this treatment, has paved the way for the development of future gene transfer techniques based on similar transfer methods, as well as novel treatment vectors, such as stem cell transfer.http://dx.doi.org/10.1100/tsw.2009.102 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Arnold Melman Kelvin P. Davies |
| spellingShingle |
Arnold Melman Kelvin P. Davies Gene Therapy in the Management of Erectile Dysfunction (ED): Past, Present, and Future The Scientific World Journal |
| author_facet |
Arnold Melman Kelvin P. Davies |
| author_sort |
Arnold Melman |
| title |
Gene Therapy in the Management of Erectile Dysfunction (ED): Past, Present, and Future |
| title_short |
Gene Therapy in the Management of Erectile Dysfunction (ED): Past, Present, and Future |
| title_full |
Gene Therapy in the Management of Erectile Dysfunction (ED): Past, Present, and Future |
| title_fullStr |
Gene Therapy in the Management of Erectile Dysfunction (ED): Past, Present, and Future |
| title_full_unstemmed |
Gene Therapy in the Management of Erectile Dysfunction (ED): Past, Present, and Future |
| title_sort |
gene therapy in the management of erectile dysfunction (ed): past, present, and future |
| publisher |
Hindawi Limited |
| series |
The Scientific World Journal |
| issn |
1537-744X |
| publishDate |
2009-01-01 |
| description |
In the past, many researchers considered viral vectors to be the most promising candidates to transfer genetic material into the corpora for the treatment of erectile dysfunction. However, at present, no viral vectors have progressed to human trials. In contrast, the use of naked gene therapy, a plasmid expressing the human Maxi-K potassium channel, is the only gene therapy treatment to be evaluated in clinical phase I trials to date. The success of these studies, proving the safety of this treatment, has paved the way for the development of future gene transfer techniques based on similar transfer methods, as well as novel treatment vectors, such as stem cell transfer. |
| url |
http://dx.doi.org/10.1100/tsw.2009.102 |
| work_keys_str_mv |
AT arnoldmelman genetherapyinthemanagementoferectiledysfunctionedpastpresentandfuture AT kelvinpdavies genetherapyinthemanagementoferectiledysfunctionedpastpresentandfuture |
| _version_ |
1725893763792896000 |